Document:

ex10-1.htm

Exhibit 10.1

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (“Agreement”) is made effective the 1st day of October 2012 (the “Effective Date”) by and between Omni Bio Pharmaceutical, Inc. (“Omni Bio” or the “Company”) and James Crapo (“Consultant”) (collectively, the “Parties”).

WHEREAS Omni Bio desires to receive the services of Consultant upon the terms and conditions set forth in this Agreement;

AND WHEREAS Consultant desires to provide to Omni Bio the services of Consultant upon the terms and conditions set forth in this Agreement;

NOW THEREFORE, in consideration of the mutual covenants and conditions hereinafter set forth, Omni Bio hereby agrees to engage the services of Consultant upon the terms and conditions set forth in the following paragraphs:

	
  

	
1)

	
DESCRIPTION OF SERVICES (“Services”) – Omni Bio engages Consultant to manage its Fc-AAT development and marketing programs, which include oversight of the product development of the Company’s Fc-AAT molecules, including management of Charles Dinarello, Soohyun Kim and other scientists and collaborators for their work in the product development of Fc-AAT; oversight of all patent prosecution related to Fc-AAT; oversight for the Company’s scientific and commercial work with iBio; oversight of the Company’s relationship with CellTrion (both product and commercial development)

	
  

	
2)

	
TERM:  This Agreement shall take effect on the Effective Date and shall remain in effect for six (6) months (October 1, 2012 to March 31, 2013, but may be terminated as permitted herein. This Agreement may be renewed upon mutual agreement by the Parties.

	
  

	
3)

	
COMPENSATION:

	
  

	
a.

	
Cash payment of $7,500 per month – Six (6) monthly payments

	
  

	
b.

	
Common stock purchase warrants 500,000, exercisable at closing price of Company common stock on date of grant; vesting – one half upon execution of this agreement and one half on last day of this agreement

	
  

	
c.

	
Company purchase of D&O 6 year tail policy on behalf of Consultant.  One-half of the cost of policy to be deducted from cash compensation in 3) a. above.  Cost of policy is equal to $35,000; $3.0 million coverage.

	
  

	
4)

	
AUTHORIZED EXPENSES - Omni Bio shall reimburse Consultant for reasonable pass-through and out-of-pocket expenses actually incurred by Consultant in connection with the Services for which Omni Bio has pre-approved and expressly agreed to be responsible (“Authorized Expenses”).  Consultant shall keep full and accurate records and documentation reasonably satisfactory to Omni Bio (such as receipts and vendor invoices) supporting any Authorized Expenses.

 

  

  

  

 

With respect to travel:

 

	
  

	
a.

	
All US domestic air travel will be booked and traveled as Coach Class by Consultant using an air carrier, route, and aircraft approved by Consultant;

	
  

	
b.

	
All international air travel will be booked and traveled as Business Class (or First Class on two class service aircraft) by Consultant using an air carrier, route, and aircraft approved by Consultant

 

	
  

	
5)

	
CONFIDENTIALITY/PROPRIETARY INFORMATION:  Consultant will abide by the terms and provisions of a Confidentiality/Proprietary Information Agreement (copy attached hereto as an Exhibit A) and further agrees that, unless expressly waived by Omni Bio in writing, Consultant will require any and all persons who have access to confidential information of Omni Bio to execute copies of agreements substantially similar to Exhibit A and that notwithstanding any other terms herein; Exhibit A remains in full force and effect; and Consultant expressly agrees that: a) at no time during the term or during a two (2) year period following the end of the Term (including any extensions thereto) shall Consultant compete with Omni Bio; b) all proprietary information and other information concerning Omni Bio acquired pursuant to the service of Consultant to Omni Bio shall at all times be and remain the sole property of Omni Bio regardless of how such proprietary information is stored and upon termination of this Agreement (w/o retaining copies), Consultant shall return all such proprietary information to Omni Bio on whatever medium it is evidenced (including w/o limitation paper files, computer memory media, etc.).

	
  

	
6)

	
ASSIGNMENT OF INTELLECTUAL PROPERTY:  Consultant will assign to Company any and all future intellectual property not currently assigned to Company that may be filed as applications with any patent jurisdiction related to research and development work in Fc-AAT by Omni, Dr. Charles Dinarello, Dr. Soohyun Kim and their scientists, collaborators.

	
  

	
7)

	
TERMINATION.

 

	
  

	
a)

	
Either party may terminate this Agreement for convenience and without cause by providing written notice to the other party at least thirty (30) days in advance of the intended termination date.

 

	
  

	
b)

	
Either party may terminate this Agreement immediately upon any breach of this Agreement, as the case may be, by the other party and the failure of the breaching party to cure such breach within thirty (30) days of receipt of written notice of such breach from the non-breaching party.

 

	
  

	
c)

	
Upon receiving any notice of termination from Omni Bio, Consultant shall use its best efforts to: (i) promptly wind down its work on the Services to be performed; (ii) refrain from entering into any non-cancelable commitments; and (iii) mitigate any further Authorized Expenses.

 

	
  

	
d)

	
Omni Bio’s liability for any work terminated prior to completion of all Services to be performed pursuant to the Agreement shall be limited to Authorized Expenses incurred.

 

	
  

	
e)

	
Unless terminated earlier pursuant to Section 6) a. through 6) d. above, the Agreement will terminate upon expiration of its stated term.

 

  

  

  

 

	
  

	
8)

	
INDEPENDENT CONTRACTOR. Consultant’s status hereunder shall be that of an independent contractor and not an agent or employee of Omni Bio. Neither party is, nor shall claim to be, a legal agent, representative, partner or employee of the other, and neither shall have the right or authority to contract in the name of the other nor shall it assume or create any obligations, debts, accounts or liabilities for the other.  In no event shall Consultant have any authority to enter into any contract or commitment in the name of or on behalf of Omni Bio, and Consultant shall not hold itself out as having authority to do so without Omni Bio’s prior written authorization.

 

	
  

	
9)

	
ASSIGNMENT AND DELEGATION.  Each Party may assign all of its rights and obligations hereunder, by written notice to the other Party, to a successor-in-interest or transferee (whether by merger, consolidation, purchase or otherwise) of either all or substantially all of the assets or shares of such Party or the part of the business of such Party to which this Agreement relates. This Agreement shall be binding upon Omni Bio and Consultant and their respective successors and assigns and any successor or assign of any substantial portion of the Omni Bio’s or Consultant’s respective businesses and/or assets.

 

	
  

	
10)

	
CONTROLLING LAW.  The validity, interpretation and performance of this Agreement and any dispute connected herewith shall be governed by and construed in accordance with the laws of the State of Colorado, without regard to its conflict of laws principles.

 

	
  

	
11)

	
ARBITRATION.  Any controversy or claim arising out of or relating to this contract, or the breach thereof, shall be settled by arbitration in accordance of the rules of the American Arbitration Association, and judgment upon the award rendered by the arbitrator(s) shall be entered in any court having jurisdiction thereof. For that purpose, the parties hereto consent to the jurisdiction and venue of an appropriate court located in Arapahoe County, State of Colorado.  All fees and expenses of the arbitration shall be borne by the parties equally.  However, each party shall bear the expense of its own counsel, experts, witnesses and preparation and presentation of proof. In the event that litigation results from or arises out of this Agreement or the performance thereof, the parties agree to reimburse the prevailing party's reasonable attorney's fees, court costs, and all other expenses, whether or not taxable by the court as costs, in addition to any other relief to which the prevailing party may be entitled.  In such event, no action shall be entertained by said court or any court of competent jurisdiction if filed more than five (5) years subsequent to the date the cause(s) of action actually accrued regardless of whether damages were otherwise as of said time calculable.

 

	
  

	
12)

	
AMENDMENT; NO WAIVER.   Any amendments or modifications to this Agreement shall be done in writing and signed by authorized representatives of both parties.  Either party’s failure to insist on compliance or enforcement of any provision of this Agreement shall not affect its validity or enforceability or constitute a waiver of future enforcement of that provision or of any other provision of this Agreement.

 

	
  

	
13)

	
SEVERABILITY. Should there be any conflict between any provisions hereof and any present or future statute, law, ordinance, regulation, or other pronouncement having the force of law, the latter shall prevail, but the provision of this Agreement affected thereby shall be curtailed and limited only to the extent necessary to bring it within the requirements of the law, and the remaining provisions of this Agreement shall remain in full force and effect.

 

  

  

  

 

	
  

	
14)

	
AGENCY.  It is understood and agreed that Consultant will act under this Agreement as an independent contractor with duties solely to the Omni Bio and nothing in this Agreement or the nature of Consultant’s services in connection with this Agreement or otherwise shall be deemed to create a fiduciary duty or fiduciary or agency relationship between Consultant and Omni Bio or its stockholders, employees or creditors, and Omni Bio agrees that it shall not make, and hereby waives, any claim based on an assertion of such fiduciary duty or relationship.

 

	
  

	
15)

	
THIRD PARTY BENEFICIARIES.  It is agreed that Consultant has been retained to provide services to Omni Bio, and not to any other person, and the Agreement is not intended to confer rights upon any person (including shareholders, employees or creditors of Omni Bio) not a party hereto.

 

	
  

	
16)

	
CONSTRUCTION. Each party hereto has had an opportunity to review and revise this Agreement, so the rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation or construction of this Agreement.

 

	
  

	
17)

	
ENTIRE AGREEMENT.   This Agreement (including any Exhibits, Schedules or Addenda attached hereto) and any Appendices incorporated herein contain the entire agreement of the Parties with respect to the subject matter hereof and supersede any prior written or oral agreements or understandings.  No representations were made or relied upon by either party other than those that are expressly set forth in this Agreement.  In the event of any conflict between the provisions of this Agreement and the provisions of any Appendix, the terms of this Agreement shall prevail.  No term, condition, proposal or other document provided or generated by Consultant shall have any force and effect with respect to the subject matter hereof unless Omni Bio has expressly and specifically agreed to that term, condition, proposal or document in writing.

 

	
  

	
18)

	
HEADINGS.   The captions to the Sections hereof are not a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation.

 

	
  

	
19)

	
COUNTERPARTS.   This Agreement may be executed in one (1) or more duplicate originals, all of which together shall be deemed one and the same instrument.

 

  

  

  

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the first above written date.

 

	Omni Bio Pharmaceutical, Inc.	 	James D. Crapo
	By:	
                                                                

	 	By:	
                                                                

	Name: 	
Steven Bathgate

	 	Name:	
James Crapo

	Title:	
Interim Chief Executive Officer

	 	Title:	
                                                                

	Date:	
                                                                

	 	Date:ex10-2.htm

Exhibit 10.2

WARRANT – CON #14

WARRANT TO PURCHASE SHARES

OF COMMON STOCK

OF OMNI BIO PHARMACEUTICAL, INC.

Warrant to Purchase 500,000 Shares of Common Stock

(subject to adjustment as set forth herein)

Exercise Price $0.35 Per Share

(subject to adjustment as set forth herein)

VOID AFTER 5 P.M., MST, October 1, 2019

THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") OR REGISTERED OR QUALIFIED UNDER ANY OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS.  THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, OR OTHERWISE TRANSFERRED, IN WHOLE OR IN PART, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR QUALIFICATION FILED IN ACCORDANCE WITH THE ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT.

Omni Bio Pharmaceutical, Inc. (“Omni”), 5350 South Roslyn, Suite 430, Greenwood Village, CO 80111, (the "Company"), hereby certifies that, for value received, James Crapo, 4650 S. Forest Street, Englewood, CO 80110 (who, together with any subsequent holder of this warrant (“Warrant”), is referred to as the "Holder"), is entitled, subject to the terms and conditions set forth below, to purchase from the Company at any time before 5 PM, MDT, on October 1, 2019 ("Expiration Date”), up to Five hundred thousand (500,000) shares of the Company's $.001 par value Common Stock (the "Shares") at a purchase price of $0.35 per Share (the "Exercise Price").

The term "Warrant" as used herein shall include this Warrant and any Warrants issued in substitution for or replacement of this Warrant, or any Warrants into which this Warrant may be divided or exchanged.  The number and character of the securities purchasable upon exercise of this Warrant and the Exercise Price are subject to adjustment as provided below.

	
  

	
1.

	
Vesting of Warrants  The Warrants shall vest and become exercisable as follows:

	
  

	
(a)

	
Two hundred fifty thousand (250,000) shall vest and become exercisable effective October 1, 2012;

	
  

	
(b)

	
Two hundred fifty thousand (250,000) shall vest and become exercisable effective March 31, 2013.

  

1

  

 

2.      Exercise of Warrant.

	
  

	
(a)

	
Subject to the other terms and conditions of this Warrant, the purchase rights evidenced by this Warrant may be exercised in whole or in part at any time, and from time to time before the Expiration Date, by the Holder's presentation and surrender of this Warrant to the Company at its principal office, accompanied by a duly executed Notice of Exercise, in the form attached to and by this reference incorporated in this Warrant as Exhibit A, and by payment of the aggregate Exercise Price, in immediately available funds, for that number of Shares specified in the Notice of Exercise.  In the event this Warrant is exercised in part only, as soon as is practicable after the presentation and surrender of this Warrant to the Company for exercise, the Company shall execute and deliver to the Holder a new Warrant, containing the same terms and conditions as this Warrant, evidencing the right of the Holder to purchase that number of Shares as to which this Warrant has not been exercised.

 

	 	
(b)

	
Upon receipt of this Warrant by the Company as described in subsection (a) above, the Holder shall be deemed to be the holder of record of the Shares issuable upon such exercise, notwithstanding that the transfer books of the Company may then be closed or that certificates representing such Shares may not have been prepared or actually delivered to the Holder.

3.      Anti-Dilution Provisions.

	 	
3.1 

	
Stock Splits, Dividends, Etc.

	
  

	
(a)

	
If the Company shall at any time subdivide its outstanding shares of Common Stock (or other securities at the time receivable upon the exercise of the Warrant) by recapitalization, reclassification or split-up thereof, or if the Company shall declare a stock dividend or distribute shares of Common Stock to its stockholders, the number of shares of Common Stock subject to this Warrant immediately prior to such subdivision shall be proportionately increased, and if the Company shall at any time combine the outstanding shares of Common Stock by recapitalization, reclassification or combination thereof, the number of shares of Common Stock subject to this Warrant immediately prior to such combination shall be proportionately decreased. Any such adjustment and adjustment to the Exercise Price pursuant to this 3 shall be effective at the close of business on the effective date of such subdivision or combination or if any adjustment is the result of a stock dividend or distribution then the effective date for such adjustment based thereon shall be the record date therefore.

	
  

	
(b)

	
Whenever the number of shares of Common Stock purchasable upon the exercise of this Warrant is adjusted, as provided in this Section 3, the Exercise Price shall be adjusted to the nearest cent by multiplying such Exercise Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise immediately prior to such adjustment, and (y) the denominator of which shall be the number of shares of Common Stock so purchasable immediately thereafter.

	
  

	
3.2

	
Adjustment for Reorganization, Consolidation, Merger, Etc.  In case of any reorganization of the Company (or any other corporation, the securities of which are at the time receivable on the exercise of this Warrant) shall consolidate with or merge into another corporation or convey all or substantially all of its assets to another corporation, then, and in each such case, the Holder of this Warrant upon the exercise at any time after the consummation of such reorganization, consolidation, merger or conveyance, shall be entitled to receive, in lieu of the securities and property receivable upon the exercise of this Warrant prior to such consummation, the securities or property to which such Holder would have been entitled upon such consummation if such Holder had exercised this Warrant immediately prior thereto; in each such case, the terms of this Warrant shall be applicable to the securities or property received upon the exercise of this Warrant after such consummation.

	
  

	
3.3

	
Certificate as to Adjustments.  In each case of an adjustment in the number of shares of Common Stock receivable on the exercise of this Warrant, the Company at its expense shall promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate executed by an officer of the Company setting forth such adjustment and showing the facts upon which such adjustment is based.  The Company shall forthwith mail a copy of each such certificate to each Holder.  The failure to prepare or provide such certificate shall not modify the rights of any party hereunder.

	 	
3.4 

	
Notices of Record Date, Etc.  In case:

	
  

	
(a)

	
the Company shall take a record of the holders of its Common Stock (or other securities at the time receivable upon the exercise of this Warrant) for the purpose of entitling them to receive any dividend (other than a cash dividend at the same rate as the rate of the last cash dividend theretofore paid) or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities, or to receive any other right; or

	
  

	
(b)

	
of any voluntary or involuntary dissolution, liquidation or winding-up of the Company, then, and in each such case, the Company shall mail or cause to be mailed to each Holder a notice specifying, as the case may be, (i) the date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which such reorganization, reclassification, consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the time, if any, to be fixed, as to which the holders of record of Common Stock (or such other securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange their shares of Common Stock (or such other securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, conveyance, dissolution, liquidation or winding-up.  Such notice shall be mailed at least twenty (20) days prior to the date therein specified, and this Warrant may be exercised prior to said date during the term of this Warrant.

  

2

  

 

	
  

	
3.5

	
Threshold for Adjustments.  Anything in this Section 3 to the contrary notwithstanding, the Company shall not be required to give effect to any adjustment until the cumulative resulting adjustment in the Exercise Price pursuant to this Section 3 shall have required a change of the Exercise Price by at least $.01, but when the cumulative net effect of more than one adjustment so determined shall be to change the Exercise Price by at least $.01, such full change in the Exercise Price shall thereupon be given effect.  No adjustment shall be made by reason of the issuance of shares upon conversion rights, stock issuance rights or similar rights currently outstanding or any change in the number of treasury shares held by the Company.

	
  

	
4.

	
Reservation of Shares. The Company hereby agrees that at all times prior to the Expiration Date, it will have authorized and will reserve and keep available for issuance and delivery to the Holder that number of Shares that may be required from time to time for issuance and delivery upon the exercise of the then unexercised portion of this Warrant and all other similar Warrants then outstanding and unexercised.

	 	
5. 

	
Representations of the Holder.

	
  

	
(a)

	
The Holder represents and warrants that the Holder is acquiring this Warrant and the Shares solely for the Holder’s own.  The Holder also represents that the entire legal and beneficial interests of this Warrant and Shares the Holder is acquiring are being acquired for, and will be held for, the Holder’s account only.

	
  

	
(b)

	
The Holder understands that this Warrant and the Shares have not been registered under the Act, or the securities laws of any applicable state, on the basis that no distribution or public offering of the stock of the Company is to be effected.  The Holder realizes that the basis for the exemption may not be present if, notwithstanding the Holder’s representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities.  The Holder has no such present intention.

	 	
(c)

	
The Holder recognizes that this Warrant and the Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available.  The Holder recognizes that the Company has no obligation to register this Warrant or the Shares, or to comply with any exemption from such registration. This Warrant, the Shares, and all other securities issued or issuable upon exercise of this Warrant, may not be offered, sold or transferred, in whole or in part, except in compliance with the Act, and except in compliance with all applicable state securities statutes.

	
  

	
(d)

	
The Holder is aware that neither this Warrant nor the Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met.

	
  

	
(e)

	
The Holder understands and agrees that all certificates evidencing the Exercise Shares shall bear legends substantially in the form of the following:

  

3

  

 

	
  

	
"The securities represented by this Certificate have not been registered under the Securities Act of 1933 ("the Act") and are 'restricted securities' as that term is defined in Rule 144 under the Act.  The securities may not be offered for sale, sold or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act, the availability of which is to be established to the satisfaction of the Company."

	
  

	
6.

	
Rights of the Holder.  The Holder shall not be entitled to any rights as a shareholder in the Company by reason of this Warrant, either at law or equity, except as specifically provided for herein.  The Company covenants, however, that for so long as this Warrant is at least partially unexercised, it will furnish any Holder of this Warrant, upon the written request by the Holder, with copies of all reports and communications furnished to the shareholders of the Company.

	
  

	
7.

	
Charges Due Upon Exercise.  The Company shall pay any and all issue or transfer taxes, including, but not limited to, all federal or state taxes, that may be payable with respect to the transfer of this Warrant or the issue or delivery of Shares upon the exercise of this Warrant.

	
  

	
8.

	
Shares to be Fully Paid.  The Company covenants that all Shares that may be issued and delivered to a Holder of this Warrant upon the exercise of this Warrant will be, upon such delivery, validly and duly issued, fully paid and non-assessable.

	
  

	
9.

	
Notices.  All notices, certificates, requests, or other similar items provided for in this Warrant shall be in writing and shall be personally delivered or deposited in the United States mail, postage prepaid, addressed to the respective party as indicated in the portions of this Warrant preceding Section 1.  All notices shall be deemed to be delivered upon personal delivery.  The addresses of the parties may be changed, and addresses of other Holders and holders of Shares may be specified, by written notice delivered pursuant to this Section 9.  The Company's principal office shall be deemed to be the address provided pursuant to this Section 9 for the delivery of notices to the Company.

	 	
10.

	
Applicable Law.  This Warrant shall be governed by and construed in accordance with the laws of the State of Colorado, and courts located in Colorado shall have exclusive jurisdiction over all disputes arising hereunder except as provided in Section 10 hereof.

	 	
11.

	
Dispute Resolution. The parties shall attempt in good faith to resolve any controversy or claim arising out of or relating to this Warrant, or the breach, termination, or validity thereof (a “Dispute”) promptly by negotiation between the parties.  If a Dispute has not been resolved within thirty (30) days by negotiation, the parties shall attempt to mediate the Dispute through the selection of a mutually agreeable mediator who shall conduct such mediation in confidence.  If a Dispute is not resolved by mediation, then the Dispute shall be settled by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association, and governed by the United States Arbitration Act, 9 U.S.C. §§ 1-16, except as otherwise provided herein.  Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof.  The place of arbitration shall be Arapahoe County, Colorado.  Each party shall be responsible for his own attorney fees incurred during any phase of dispute resolution.  The arbitrator shall apply the law to the dispute in the same manner as a judge as though the dispute was before a court of law of the State of Colorado.  The arbitrator shall have the authority to award any remedy or relief that a court of the State of Colorado could order or grant, including, without limitation, specific performance of any obligation created under the Agreement, the issuance of an injunction, or the imposition of sanctions for abuse or frustration of the arbitration process.  Notwithstanding the foregoing, the arbitrator shall not have authority to award punitive damages.  The parties shall take all reasonable steps necessary to conduct a hearing no later than forty-five (45) days after submission of the matter to arbitration.  The arbitrator shall render his decision within fifteen (15) days after the close of the arbitration hearing.  The arbitration award shall be in writing and shall specify the factual and legal bases for the award.

  

4

  

12.    Market Standoff Agreement. The Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by the Holder, for a period of time specified by the managing underwriter(s) or placement agent(s), as applicable, (not to exceed one hundred eighty (180) days) following the effective date of a primary underwritten public offering by the Company of any Common Stock (or other securities) or private placement by the Company of any Common Stock (or other securities).  Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the managing underwriter(s) or placement agent(s) which are consistent with the foregoing or which are necessary to give further effect thereto.  In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period.  The underwriters or placement agents of the Company’s stock are intended third party beneficiaries of this Section 12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

 

13.    Change of Control of the Company. As used herein, a "Change of Control" shall be deemed to have occurred if:

         (a)      Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) (other than persons who are stockholders on the effective date of the Plan) becomes a "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a change of ownership resulting from the death of a stockholder and a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company immediately prior to the transaction will beneficially own, immediately after the transaction, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); or

         (b)      The stockholders of the Company approve (or, if stockholder approval is not required, the Board approves) an agreement providing for (i) the merger or consolidation of the Company with another corporation where the stockholders of the Company immediately prior to the merger or consolidation will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote), (ii) the sale or other disposition of all or substantially all of the assets of the Company, or (iii) a liquidation or dissolution of the Company.

14.    Consequences of a Change of Control

         (a)      Notice and Acceleration.    Upon a Change of Control, (i) the Company shall provide the Holder a written notice of such Change of Control, (ii) on the date prior to the Change of Control the Warrant shall automatically accelerate and become fully exercisable, and (iii) the restrictions and conditions on the Warrant shall immediately lapse.

 

         (b)     Assumption of Warrant.    Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), any outstanding portion of the Warrant that is not exercised shall be assumed by, or replaced with comparable warrants and/or options by, the surviving corporation.

 

15.    Termination of Employment, Services, Disability or Death

 

         (a)       In the event the Holder ceases to be employed by, or provide service to, the Company for any reason other than Disability, death, or termination for Cause, any unvested Warrant Shares will be forfeited and cancelled on the date on which the Holder ceases to be employed by, or provide service to, the Company.

 

         (b)      In the event the Holder ceases to be employed by, or provide service to, the Company due to termination for Cause by the Company, this Warrant shall terminate as of the date the Holder ceases to be employed by, or provide service to, the Company. In addition, notwithstanding any other provisions of this Section 15, if the Company determines that the Holder has engaged in conduct that constitutes Cause at any time while the Holder is employed by, or providing service to, the Company or after the Holder's termination of employment or service, this Warrant shall immediately terminate, and the Holder shall automatically forfeit all Shares underlying any exercised portion of this Warrant for which the Company has not yet delivered the share certificates, upon refund by the Company of the Exercise Price paid by the Holder for such shares. Upon any exercise of this Warrant, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in forfeiture.

 

        (c)       In the event the Holder ceases to be employed by, or provide service to, the Company due to Disability or death, all Warrant Shares shall immediately become vested and exercisable. In the circumstance of death, this Warrant shall pass to the Holder’s estate.

 

For purposes of this Section 15:

        (1)      "Employed by, or provide service to, the Company" shall mean employment or service as an employee, non-employee director, advisor or consultant (so that, for purposes of exercising this Warrant, the Holder shall not be considered to have terminated employment or service until the Holder ceases to be an employee, non-employee director, advisor or consultant).

  

5

  

	
  

	 	 

       (2)      "Disability" shall mean the Holder becoming disabled within the meaning of Section 22(e)(3) of the Internal Revenue Code of 1986, as amended.

 

       (3)      "Cause" shall mean, except to the extent specified otherwise by the Company or its Board of Directors (the “Board”), a finding by the Company or Board that the Holder (i) has breached his or her employment or service contract with the Company, (ii) has engaged in disloyalty to the Company, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty in the course of his or her employment or service, (iii) has disclosed trade secrets or confidential information of the Company to persons not entitled to receive such information or (iv) has engaged in such other behavior detrimental to the interests of the Company as the Company or Board determine.

16. Miscellaneous Provisions.

  (a)     Subject to the terms and conditions contained herein, this Warrant shall be binding on the Company and its successors and shall inure to the benefit of the original Holder, its successors and assigns and all holders of Shares and the exercise of this Warrant in full shall not terminate the provisions of this Warrant as it relates to holders of Shares.

 

  (b)     If the Company fails to perform any of its obligations hereunder, it shall be liable to the Holder for all damages, costs and expenses resulting from the failure, including, but not limited to, all reasonable attorney's fees and disbursements.

 

  (c)     This Warrant cannot be changed or terminated or any performance or condition waived in whole or in part except by an agreement in writing signed by the party against whom enforcement of the change, termination or waiver is sought.

 

  (d)     If any provision of this Warrant shall be held to be invalid, illegal or unenforceable, such provision shall be severed, enforced to the extent possible, or modified in such a way as to make it enforceable, and the invalidity, illegality or unenforceability shall not affect the remainder of this Warrant.

 

  (e)    The Company agrees to execute such further agreements, conveyances, certificates and other documents as may be reasonably requested by the Holder to effectuate the intent and provisions of this Warrant.

 

  (f)     Paragraph headings used in this Warrant are for convenience only and shall not be taken or construed to define or limit any of the terms or provisions of this Warrant.  Unless otherwise provided, or unless the context shall otherwise require, the use of the singular shall include the plural and the use of any gender shall include all genders.

  

6

  

 

	 	 	 	
OMNI BIO PHARMACEUTICAL, INC.

	ATTEST:	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By	
 

	 	
By

	 
	 	Robert Ogden	 	 	Vicki Barone
	 	Secretary 	 	 	Chairperson of the Board
	 	 	 	 	 
	 	 	 	 	 
	Date	 	 	Date	 
	 	 	 	 	 

 

  

7

  

EXHIBIT A

NOTICE OF EXERCISE

(To be executed by a Holder desiring to exercise the right to purchase Shares pursuant to a Warrant.)

The undersigned Holder of a Warrant hereby

 

(a)    irrevocably elects to exercise the Warrant to the extent of purchasing _______________ Shares;

 

(b)    makes payment in full of the aggregate Exercise Price for those Shares in the amount of $_____________ by the delivery of immediately available funds in the amount of $ ____________; 

(c)    requests that certificates evidencing the securities underlying such Shares be issued in the name of the undersigned, or, if the name and address of some other person is specified below, in the name of such other person:

 

 

  

  

(Name and address of person other than the

undersigned in whose name Shares are to be registered)

 

(d)    requests, if the number of Shares purchased are not all the Shares purchasable pursuant to the unexercised portion of the Warrant, that a new Warrant of like tenor for the remaining Shares purchasable pursuant to the Warrant be issued and delivered to the undersigned at the address stated below.

	Dated:	
 

	 	
 

	 
	 	 	 	 	Signature
	 	 	 	 	
(This signature must conform in all respects

	 	 	 	 	to the name of the Holder as specified on the 

face of the Warrant.)

	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 
	
Social Security Number

or Employer ID Number

	 	 	Printed Name
	 	 	Address:       	 
	 	 	 	 
	 	 	 	 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]